Anti-oncogenic activities of cyclin D1b siRNA on human bladder cancer cells via induction of apoptosis and suppression of cancer cell stemness and invasiveness

Kim,Chul Jang; Terado,Tokio; Tambe,Yukihiro; Mukaisho,Ken-Ichi; Sugihara,Hiroyuki; Kawauchi,Akihiro; Inoue,Hirokazu

doi:10.3892/ijo.2017.4194

Anti-oncogenic activities of cyclin D1b siRNA on human bladder cancer cells via induction of apoptosis and suppression of cancer cell stemness and invasiveness

Authors:
- Chul Jang Kim
- Tokio Terado
- Yukihiro Tambe
- Ken-Ichi Mukaisho
- Hiroyuki Sugihara
- Akihiro Kawauchi
- Hirokazu Inoue
View Affiliations

Affiliations: Department of Urology, Kohka Public Hospital, Minakuchi-cho, Kohka, Shiga 528-0074, Japan, Department of Stem Cell Biology and Regenerative Medicine, Shiga University of Medical Science, Setatsukinowa-cho, Otsu, Shiga 520-2192, Japan, Division of Microbiology and Infectious Diseases, Shiga University of Medical Science, Setatsukinowa-cho, Otsu, Shiga 520-2192, Japan, Division of Molecular and Diagnostic Pathology, Shiga University of Medical Science, Setatsukinowa-cho, Otsu, Shiga 520-2192, Japan, Division of Urology, Shiga University of Medical Science, Setatsukinowa-cho, Otsu, Shiga 520-2192, Japan
Published online on: November 7, 2017 https://doi.org/10.3892/ijo.2017.4194
Pages: 231-240

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The human cyclin D1 gene generates two major isoforms, cyclin D1a and cyclin D1b, by alternative splicing. Although cyclin D1b mRNA is hardly expressed in normal human tissues, it is detected in approximately 60% of human bladder cancer tissues and cell lines. In the present study, to assess the therapeutic ability of cyclin D1b siRNA, we investigated the anti-oncogenic effects of cyclin D1b siRNA on human bladder cancer cell lines, SBT31A and T24, which express cyclin D1b mRNA. Knockdown of cyclin D1b by specific siRNA significantly suppressed cell proliferation, in vitro cell invasiveness and three-dimensional (3D) spheroid formation in these cell lines. Cell cycle analyses revealed that cyclin D1b siRNA inhibited G1-S transition in T24 cells. The increase in the sub-G1 fraction, morphological aberrant nuclei with nuclear fragmentation and caspase-3 activity in SBA31A cells treated with cyclin D1b siRNA showed that cyclin D1b siRNA induced apoptosis. In T24 cells, knockdown of cyclin D1b suppressed the expression of the stem cell marker CD44. Knockdown of cyclin D1b or CD44 suppressed the invasiveness under 3D spheroid culture conditions and expression of N-cadherin. Tumor growth of SBT31A cells in nude mice was significantly inhibited by cyclin D1b siRNA. Taken together, these results indicate that knockdown of cyclin D1b suppresses the malignant phenotypes of human bladder cancer cells via induction of apoptosis and suppression of cancer cell stemness and epithelial-mesenchymal transition. Applying cyclin D1b siRNA will be a novel therapy for cyclin D1b-expressing bladder cancers.

View Figures

View References

1	Knudsen KE, Diehl JA, Haiman CA and Knudsen ES: Cyclin D1: Polymorphism, aberrant splicing and cancer risk. Oncogene. 25:1620–1628. 2006. View Article : Google Scholar : PubMed/NCBI
2	Sherr CJ: D-type cyclins. Trends Biochem Sci. 20:187–190. 1995. View Article : Google Scholar : PubMed/NCBI
3	Lukas J, Parry D, Aagaard L, Bartkova J, Strauss M, Peters G and Bartek J: Retinoblastoma-protein-dependent cell-cycle inhibition by tumour suppressor p16. Nature. 375:503–506. 1995. View Article : Google Scholar : PubMed/NCBI
4	Musgrove EA, Caldon CE, Barraclough J, Stone A and Sutherland RL: Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 11:558–572. 2011. View Article : Google Scholar : PubMed/NCBI
5	Hosokawa Y, Gadd M, Smith AP, Koerner FC, Schmidt EV and Arnold A: Cyclin D1 (PRAD1) alternative transcript b: Full-length cDNA cloning and expression in breast cancers. Cancer Lett. 113:123–130. 1997. View Article : Google Scholar : PubMed/NCBI
6	Lu F, Gladden AB and Diehl JA: An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 63:7056–7061. 2003.PubMed/NCBI
7	Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, Senderowicz AM, Conti CJ and Knudsen ES: Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem. 278:30339–30347. 2003. View Article : Google Scholar : PubMed/NCBI
8	Burd CJ, Petre CE, Morey LM, Wang Y, Revelo MP, Haiman CA, Lu S, Fenoglio-Preiser CM, Li J, Knudsen ES, et al: Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci USA. 103:2190–2195. 2006. View Article : Google Scholar : PubMed/NCBI
9	Holley SL, Parkes G, Matthias C, Bockmühl U, Jahnke V, Leder K, Strange RC, Fryer AA and Hoban PR: Cyclin D1 polymorphism and expression in patients with squamous cell carcinoma of the head and neck. Am J Pathol. 159:1917–1924. 2001. View Article : Google Scholar : PubMed/NCBI
10	Howe D and Lynas C: The cyclin D1 alternative transcripts [a] and [b] are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241. Haematologica. 86:563–569. 2001.PubMed/NCBI
11	Bala S and Peltomäki P: CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res. 61:6042–6045. 2001.PubMed/NCBI
12	Paronetto MP, Cappellari M, Busà R, Pedrotti S, Vitali R, Comstock C, Hyslop T, Knudsen KE and Sette C: Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. Cancer Res. 70:229–239. 2010. View Article : Google Scholar :
13	Kim CJ, Nishi K, Isono T, Okuyama Y, Tambe Y, Okada Y and Inoue H: Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells. Mol Carcinog. 48:953–964. 2009. View Article : Google Scholar : PubMed/NCBI
14	Kim CJ, Tambe Y, Mukaisho K, Sugihara H, Isono T, Sonoda H, Shimizu T, Kondoh G and Inoue H: Female-specific rectal carcinogenesis in cyclin D1b transgenic mice. Carcinogenesis. 35:227–236. 2014. View Article : Google Scholar
15	Kim CJ, Tambe Y, Mukaisho KI, Sugihara H, Kawauchi A and Inoue H: Akt-dependent activation of Erk by cyclin D1b contributes to cell invasiveness and tumorigenicity. Oncol Lett. 12:4850–4856. 2016.
16	Kim CJ, Yuasa T, Kushima R, Tomoyoshi T and Seto A: Antitumor killer lymphocytes in the peripheral blood of a patient with transitional cell carcinoma of the bladder. Int J Urol. 5:230–236. 1998. View Article : Google Scholar : PubMed/NCBI
17	Tambe Y, Yoshioka-Yamashita A, Mukaisho K, Haraguchi S, Chano T, Isono T, Kawai T, Suzuki Y, Kushima R, Hattori T, et al: Tumor prone phenotype of mice deficient in a novel apoptosis-inducing gene, drs. Carcinogenesis. 28:777–784. 2007. View Article : Google Scholar
18	Weiswald LB, Bellet D and Dangles-Marie V: Spherical cancer models in tumor biology. Neoplasia. 17:1–15. 2015. View Article : Google Scholar : PubMed/NCBI
19	Robertson FM, Ogasawara MA, Ye Z, Chu K, Pickei R, Debeb BG, Woodward WA, Hittelman WN, Cristofanilli M and Barsky SH: Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotype. J Biomol Screen. 15:820–829. 2010. View Article : Google Scholar : PubMed/NCBI
20	Xu H, Tian Y, Yuan X, Wu H, Liu Q, Pestell RG and Wu K: The role of CD44 in epithelial-mesenchymal transition and cancer development. Onco Targets Ther. 8:3783–3792. 2015.
21	Cairns P, Proctor AJ and Knowles MA: Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene. 6:2305–2309. 1991.PubMed/NCBI
22	Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z and Reuter VE: Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer. J Natl Cancer Inst. 84:1251–1256. 1992. View Article : Google Scholar : PubMed/NCBI
23	Logothetis CJ, Xu HJ, Ro JY, Hu SX, Sahin A, Ordonez N and Benedict WF: Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst. 84:1256–1261. 1992. View Article : Google Scholar : PubMed/NCBI
24	Burkhart DL and Sage J: Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 8:671–682. 2008. View Article : Google Scholar : PubMed/NCBI
25	Knudson ES and Knudson KE: Tailoring to RB: Tumor suppressor status and therapeutic response. Natl Rev. 8:714–724. 2008. View Article : Google Scholar
26	Thangavel C, Boopathi E, Liu Y, Haber A, Ertel A, Bhardwaj A, Addya S, Williams N, Ciment SJ, Cotzia P, et al: RB loss promotes prostate cancer metastasis. Cancer Res. 77:982–995. 2017. View Article : Google Scholar :
27	Wei M, Zhu L, Li Y, Chen W, Han B, Wang Z, He J, Yao H, Yang Z, Zhang Q, et al: Knocking down cyclin D1b inhibits breast cancer cell growth and suppresses tumor development in a breast cancer model. Cancer Sci. 102:1537–1544. 2011. View Article : Google Scholar : PubMed/NCBI
28	Spring FA, Dalchau R, Daniels GL, Mallinson G, Judson PA, Parsons SF, Fabre JW and Anstee DJ: The Ina and Inb blood group antigens are located on a glycoprotein of 80,000 MW (the CDw44 glycoprotein) whose expression is influenced by the In(Lu) gene. Immunology. 64:37–43. 1988.PubMed/NCBI
29	Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR and Ghatak S: Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J. 278:1429–1443. 2011. View Article : Google Scholar : PubMed/NCBI
30	Ponta H, Sherman L and Herrlich PA: CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 4:33–45. 2003. View Article : Google Scholar : PubMed/NCBI
31	Turley EA, Noble PW and Bourguignon LYW: Signaling properties of hyaluronan receptors. J Biol Chem. 277:4589–4592. 2002. View Article : Google Scholar
32	Misra S, Hascall VC, De Giovanni C, Markwald RR and Ghatak S: Delivery of CD44 shRNA/nanoparticles within cancer cells: Perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE. J Biol Chem. 284:12432–12446. 2009. View Article : Google Scholar : PubMed/NCBI
33	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
34	Polyak K and Weinberg RA: Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
35	Kim JB, Islam S, Kim YJ, Prudoff RS, Sass KM, Wheelock MJ and Johnson KR: N-Cadherin extracellular repeat 4 mediates epithelial to mesenchymal transition and increased motility. J Cell Biol. 151:1193–1206. 2000. View Article : Google Scholar : PubMed/NCBI
36	Lascombe I, Clairotte A, Fauconnet S, Bernardini S, Wallerand H, Kantelip B and Bittard H: N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clin Cancer Res. 12:2780–2787. 2006. View Article : Google Scholar : PubMed/NCBI
37	Hazan RB, Phillips GR, Qiao RF, Norton L and Aaronson SA: Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol. 148:779–790. 2000. View Article : Google Scholar : PubMed/NCBI
38	Gravdal K, Halvorsen OJ, Haukaas SA and Akslen LA: A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res. 13:7003–7011. 2007. View Article : Google Scholar : PubMed/NCBI
39	Bryan RT: Cell adhesion and urothelial bladder cancer: The role of cadherin switching and related phenomena. Philos Trans R Soc Lond B Biol Sci. 370:201400422015. View Article : Google Scholar :
40	Jäger T, Becker M, Eisenhardt A, Tilki D, Tötsch M, Schmid KW, Romics I, Rübben H, Ergün S and Szarvas T: The prognostic value of cadherin switch in bladder cancer. Oncol Rep. 23:1125–1132. 2010.PubMed/NCBI
41	Gaglione M and Messere A: Recent progress in chemically modified siRNAs. Mini Rev Med Chem. 10:578–595. 2010. View Article : Google Scholar : PubMed/NCBI
42	Herr HW, Laudone VP and Whitmore WF Jr: An overview of intravesical therapy for superficial bladder tumors. J Urol. 138:1363–1368. 1987. View Article : Google Scholar : PubMed/NCBI
43	Okamura K, Ono Y, Kinukawa T, Matsuura O, Yamada S, Ando T, Fukatsu T, Ohno Y and Ohshima S; Nagoya University Urological Oncology Group: Randomized study of single early instillation of (2″R)-4′-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer. 94:2363–2368. 2002. View Article : Google Scholar : PubMed/NCBI
44	Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, Yokota A, Segawa H, Toda Y, Kageyama S, et al: Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest. 115:978–985. 2005. View Article : Google Scholar : PubMed/NCBI